BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 37254688)

  • 1. Clinical outcomes associated with drugs for obesity and overweight: A systematic review and network meta-analysis of randomized controlled trials.
    Iannone A; Natale P; Palmer SC; Nicolucci A; Rendina M; Giorgino F; Laviola L; Di Leo A; Strippoli GFM
    Diabetes Obes Metab; 2023 Sep; 25(9):2535-2544. PubMed ID: 37254688
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials.
    Shi Q; Wang Y; Hao Q; Vandvik PO; Guyatt G; Li J; Chen Z; Xu S; Shen Y; Ge L; Sun F; Li L; Yu J; Nong K; Zou X; Zhu S; Wang C; Zhang S; Qiao Z; Jian Z; Li Y; Zhang X; Chen K; Qu F; Wu Y; He Y; Tian H; Li S
    Lancet; 2024 Apr; 403(10434):e21-e31. PubMed ID: 38582569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term effects of weight-reducing drugs in people with hypertension.
    Siebenhofer A; Winterholer S; Jeitler K; Horvath K; Berghold A; Krenn C; Semlitsch T
    Cochrane Database Syst Rev; 2021 Jan; 1(1):CD007654. PubMed ID: 33454957
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials.
    Shi Q; Wang Y; Hao Q; Vandvik PO; Guyatt G; Li J; Chen Z; Xu S; Shen Y; Ge L; Sun F; Li L; Yu J; Nong K; Zou X; Zhu S; Wang C; Zhang S; Qiao Z; Jian Z; Li Y; Zhang X; Chen K; Qu F; Wu Y; He Y; Tian H; Li S
    Lancet; 2022 Jan; 399(10321):259-269. PubMed ID: 34895470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis.
    Khera R; Murad MH; Chandar AK; Dulai PS; Wang Z; Prokop LJ; Loomba R; Camilleri M; Singh S
    JAMA; 2016 Jun; 315(22):2424-34. PubMed ID: 27299618
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of Phentermine/Topiramate in Adults with Overweight or Obesity: A Systematic Review and Meta-Analysis.
    Lei XG; Ruan JQ; Lai C; Sun Z; Yang X
    Obesity (Silver Spring); 2021 Jun; 29(6):985-994. PubMed ID: 33864346
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term effects of weight-reducing drugs in people with hypertension.
    Siebenhofer A; Jeitler K; Horvath K; Berghold A; Posch N; Meschik J; Semlitsch T
    Cochrane Database Syst Rev; 2016 Mar; 3():CD007654. PubMed ID: 26934640
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial.
    Gadde KM; Allison DB; Ryan DH; Peterson CA; Troupin B; Schwiers ML; Day WW
    Lancet; 2011 Apr; 377(9774):1341-52. PubMed ID: 21481449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular effects of phentermine and topiramate: a new drug combination for the treatment of obesity.
    Jordan J; Astrup A; Engeli S; Narkiewicz K; Day WW; Finer N
    J Hypertens; 2014 Jun; 32(6):1178-88. PubMed ID: 24621808
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interventions for weight loss in people with chronic kidney disease who are overweight or obese.
    Conley MM; McFarlane CM; Johnson DW; Kelly JT; Campbell KL; MacLaughlin HL
    Cochrane Database Syst Rev; 2021 Mar; 3(3):CD013119. PubMed ID: 33782940
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Weight-loss Effect of GLP-1RAs Glucagon-Like Peptide-1 Receptor Agonists in Non-diabetic Individuals with Overweight or Obesity: A Systematic Review with Meta-Analysis and Trial Sequential Analysis of Randomized Controlled Trials.
    Liu Y; Ruan B; Jiang H; Le S; Liu Y; Ao X; Huang Y; Shi X; Xue R; Fu X; Wang S
    Am J Clin Nutr; 2023 Sep; 118(3):614-626. PubMed ID: 37661106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand?
    Tak YJ; Lee SY
    Curr Obes Rep; 2021 Mar; 10(1):14-30. PubMed ID: 33410104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AGA Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity.
    Grunvald E; Shah R; Hernaez R; Chandar AK; Pickett-Blakely O; Teigen LM; Harindhanavudhi T; Sultan S; Singh S; Davitkov P;
    Gastroenterology; 2022 Nov; 163(5):1198-1225. PubMed ID: 36273831
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of subcutaneous semaglutide in adults with overweight or obese: a subgroup meta-analysis of randomized controlled trials.
    Zhang R; Hou QC; Li BH; Deng L; Yang YM; Li TX; Yao XQ; Yang LL; Lin XL; Liao YQ; Wang L; Liu YP; Tan J; Wan ZW; Shuai P
    Front Endocrinol (Lausanne); 2023; 14():1132004. PubMed ID: 37455913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative effects of nutraceuticals on body weight in adults with overweight or obesity: A systematic review and network meta-analysis of 111 randomized clinical trials.
    Shahinfar H; Jayedi A; Torabynasab K; Payandeh N; Martami F; Moosavi H; Bazshahi E; Shab-Bidar S
    Pharmacol Res; 2023 Oct; 196():106944. PubMed ID: 37778464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interventions to change the behaviour of health professionals and the organisation of care to promote weight reduction in children and adults with overweight or obesity.
    Flodgren G; Gonçalves-Bradley DC; Summerbell CD
    Cochrane Database Syst Rev; 2017 Nov; 11(11):CD000984. PubMed ID: 29190418
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of semaglutide 2.4 mg for weight loss in overweight or obese adults without diabetes: An updated systematic review and meta-analysis including the 2-year STEP 5 trial.
    Qin W; Yang J; Deng C; Ruan Q; Duan K
    Diabetes Obes Metab; 2024 Mar; 26(3):911-923. PubMed ID: 38016699
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.